ESR1 and breast carcinoma: To determine whether PIs have the potential to inhibit outgrowth or to induce cell death in ER+/HER2+ breast cancer cells with acquired resistance to lapatinib, we first developed lapatinib-resistant BT474 cells by culturing them in the presence of lapatinib for 10–12 weeks.